Associate Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School
Hematology
Dr. Jonathan E. Dowell, MD
|
|
Give Review
Jonathan Dowell works in the field of Hematology. He went to University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Jonathan Dowell is a published doctor as well. He has 46 publications published. The latest was: Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. Jonathan Dowell is registered with Medicare and accepts Medicare payments.
Publications
- Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer.
- Impact of comorbidity on initial treatment and overall survival in elderly head and neck Cancer patients.
- Response to letter titled: blood pressure monitoring in patients receiving bevacizumab.
- Upper extremity venous thrombosis in patients with Cancer with peripherally inserted central venous catheters: a retrospective analysis of risk factors.
- Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.
- Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies.
- A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced Malignant mesothelioma.
- Embolic stroke secondary to an indwelling catheter in a patient with a patent foramen ovale: a case report and review of the literature.
- The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for Chronic myelogenous leukemia.
- Incidence of Isolated Heparin-Induced Thrombocytopenia and Risk of Thrombosis by IgG-Specific Anti-PF4/Heparin ELISA.
- Predictors and impact of second-line chemotherapy for advanced non-small cell lung Cancer in the United States: real-world considerations for maintenance therapy.
- Risk of renal failure in Cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
- Putting lung Cancer clinical trials into perspective.
- Comparison of the 5-fluorouracil-warfarin and capecitabine-warfarin drug interactions.
- Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung Cancer in a contemporary, diverse ...
- Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate Cancer.
- Diffuse large B-cell Lymphoma in a hepatitis C virus-infected patient presenting with lactic acidosis and hypoglycemia.
- Small cell lung Cancer: are we making progress?
- The impact of consenter characteristics and experience on patient interest in clinical research.
- Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced Cancer and non-small cell lung Cancer.
- Rectal GI stromal tumor mimicking a proState mass.
- Epidermal growth factor receptor mutations in non-small cell lung Cancer: a basic science discovery with immediate clinical impact.
- Antiangiogenic therapies for mesothelioma.
- Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung Cancer.
- Case 1. Melanoma in African Americans.
- In search of affordable prescription medications.
- Chasing mutations in the epidermal growth factor in lung Cancer.
- Cancer chemotherapy targeted at reactivating the expression of epigenetically inactivated genes.
- Cancer from an unknown primary site.
- Extramedullary sites of involvement in hematologic malignancies: case 1. Multifocal intracranial involvement with mantle-cell Lymphoma.
- A randomized Phase II trial in patients with carcinoma of an unknown primary site.
- Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck Cancers.
- A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell Cancer previously treated with chemotherapy.
- Erlotinib hydrochloride.
- Amifostine and curative intent chemoradiation for compromised Cancer patients.
- A randomized trial assessing the utility of a test-dose program with taxanes.
- Images in clinical medicine. Diffuse subcutaneous air due to a perforated colonic diverticulum.
- Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting.
- Small-cell lung Cancer: translational research enroute to therapeutic advances.
- A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian Cancer patients: CALGB 9871.
- Mitomycin C provides little additional benefit in the treatment of carcinoma of unknown primary site.
- Survival in small cell lung Cancer is independent of tumor expression of VEGF and COX-2.
- EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung Cancer.
- The impact of epidermal-growth-factor-receptor mutations in response to lung-Cancer therapy.
- ERCC1 expression and outcomes in head and neck Cancer treated with concurrent cisplatin and radiation.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Vanderbilt University Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anemia
- Antiphospholipid Syndrome (APS)
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Vanderbilt University -
University of Chicago Pritzker School of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Veterans Affairs North Texas Health Care System
Drug Facts
| NPI NUMBER | 1497724983 | |
| NPPES Provider LastName | DOWELL | |
| NPPES Provider FirstName | JONATHAN | |
| NPPES Provider ZIPCode | 753907208 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 143.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 9.79 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497724983 |
| Last Name Of The Provider | DOWELL |
| First Name Of The Provider | JONATHAN |
| View All |
Similar Doctors
|
|
Dr. Fernando J. Castro-Silva, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph W. Fay, MD |
|
|
Dr. Cheryl A. Harth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lalan S. Wilfong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin F. Dietrich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James B. Brugarolas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Dennis H. Birenbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James F. Amatruda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam J. Hoffhines, MD |
|
|
Dr. Elizabeth C. Pollard, MD |
|
|
Dr. Pier P. Scaglioni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nima Sharifi, MD
This Doctor is OpenDoctor Recommended.
|